36-Year-Old Man With Productive Cough and Diffuse Rash
- The Impact of Steroids Given with Macrolide Therapy on Experimental Mycoplasma pneumoniae Respiratory Infection. Tagliabue, C.; Salvatore, C. M.; Techasaensiri, C.; Mejias, A.; Torres, J. P.; Katz, K.; Gomez, A. M.; Esposito, S.; Principi, N.; Hardy, R. D. // Journal of Infectious Diseases;10/15/2008, Vol. 198 Issue 8, p1180
Background. Systemic steroids have been advocated in addition to antimicrobial therapy for severe Mycoplasma pneumoniae pneumonia. We evaluated the efficacy of clarithromycin, dexamethasone, and combination therapy for M. pneumoniae respiratory infection. Methods. Mice infected with M....
- Monotherapy versus Dual Therapy for Community-Acquired Pneumonia in Hospitalized Patients. Martinez, Fernando J. // Clinical Infectious Diseases;5/15/2004 Supplement, Vol. 38, pS328
Several medical-specialty professional societies have suggested that combination therapy with a ï¿½-lactam plus a macrolide or doxycycline or monotherapy with a "respiratory quinolone" (i.e., levofloxacin, gatifloxacin, moxifloxacin, or gemifloxacin) are optimal first-line therapy for...
- Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review. QUN-LI DING; DAN LV; BI-JIONG WANG; QIAO-LI ZHANG; YI-MING YU; SHI-FANG SUN; ZHONG-BO CHEN; HONG-YING MA; ZAI-CHUN DENG // Experimental & Therapeutic Medicine;2015, Vol. 9 Issue 3, p829
Cryptogenic organizing pneumonia (COP) is a pulmonary disorder associated with nonspecific clinical presentations. The macrolide class of antimicrobial agents is widely used to treat infectious and inflammatory respiratory diseases in humans. The present study reports a case of COP that was...
- Is Azithromycin the First-Choice Macrolide for Treatment of Community-Acquired Pneumonia? Sánchez, Francesca // Clinical Infectious Diseases;7/1/2004, Vol. 39 Issue 1, p145
This article presents response of the author to an article about the treatment of community-acquired pneumonia (CAP) with two macrolides, clarithromycin and azithromycin. The severity of CAP in patients who have received a diagnosis of CAP in the author's hospital has been scored using the...
- Should we give long-term macrolide therapy for COPD? Crosbie, Philip A. J.; Woodhead, Mark; Albert, Richard K. // Thorax;Oct2013, Vol. 68 Issue 10, p966
In this article, the authors debate on the topic related to the macrolide therapy in patients with chronic obstructive pulmonary disease (COPD). They reported that low-dose macrolides for exacerbation prevention, should not be recommended in the management of COPD. They informed that macrolides...
- Managing hyperglycemia in CAP. // Drug Topics;12/12/2005, Vol. 149 Issue 23, pHSE12
The article provides information about managing hyperglycemia in community-acquired pneumonia (CAP). The development of hyperglycemia usually takes after three or four days of treatment and is more common than hypoglycemia. Hyperglycemia mechanism is not clear but is hypothesized as secondary to...
- Community-acquired pneumonia and use of macrolide antibiotics. MILLER, KARL // American Family Physician;10/15/1998, Vol. 58 Issue 6, p1457
Presents the abstract of the article `Implications for macrolide treatment in community-acquired pneumonia,' by L.M. Mundy, et al from the `Chest' journal dated May 1998.
- Letter to the editors. Vestbo, Jørgen; Rodriguez-Roisin, Roberto // Thorax;Apr2013, Vol. 68 Issue 4, p387
A letter to the editor is presented in response to the article "Highlights from this issue" by A. Bush A and I. Pavord in the November 2012 issue.
- Response to Vestbo and Rodrigues-Roisin. Pavord, Ian D.; Bush, Andy // Thorax;Apr2013, Vol. 68 Issue 4, p388
A response from the authors of the article "Highlights from this issue" in the November 2012 issue, which discusses the use of macrolids for the prevention of exacerbations in case of chronic obstructive pulmonary disease (COPD), is presented.